| abstract |
A pharmaceutical formulation comprising an anti-IL-17 antibody at a concentration in the range of 80 mg / ml to 150 mg / ml, citrate buffer at a concentration of 20 mM, sodium chloride at a concentration of 200 mM, polysorbate-80 at a concentration in the range of 0.02% (w / v) to 0.03% (w / v), and pH at 5.7, wherein the anti-IL-17 antibody comprises a antibody with a light chain (CL) and a heavy chain (CP), wherein said CL is the amino acid sequence of SEQ ID No. 4 and said CP is the amino acid sequence of SEQ ID No. 5. |